MedPath

FDA Approves StemCyte's REGENECYTE Cord Blood Therapy for Hematopoietic Disorders

• The FDA has approved StemCyte's Biologics License Application for REGENECYTE, a cord blood stem cell therapy, marking a significant advancement in treating blood and immune system disorders. • REGENECYTE is an allogeneic hematopoietic stem cell therapy derived from human umbilical cord blood, indicated for hematopoietic and immunologic reconstitution. • StemCyte is also exploring its cord blood products for potential therapeutic applications, including chronic fatigue syndrome, long COVID, aging-related diseases and acute stroke. • StemCyte International Ltd. is set to be listed on the Taipei Stock Exchange in December 2024, aiming to expand regenerative medicine and deliver innovative therapies globally.

StemCyte Inc., a subsidiary of StemCyte International Ltd., has received FDA approval for its Biologics License Application (BLA) for REGENECYTE™, a cord blood stem cell therapy used in hematopoietic progenitor cell transplantation for patients with blood and immune system disorders. This approval marks StemCyte as the first commercial U.S.-based biotech company to secure a biologics license for cord blood stem cell therapy.
REGENECYTE™ is an allogeneic hematopoietic stem cell therapy derived from human umbilical cord blood. It is indicated for unrelated donor hematopoietic progenitor cell transplantation alongside a preparative regimen for hematopoietic and immunologic reconstitution. The therapy is designed for patients with inherited or acquired disorders affecting the hematopoietic system, or those resulting from myeloablative treatment.

Expanding Therapeutic Applications

Beyond REGENECYTE™, StemCyte is investigating the potential of its other HPC, Cord Blood products for emerging therapeutic applications. These include chronic fatigue syndrome, aging-related diseases, and conditions associated with suboptimal health. The company is also conducting Phase II clinical trials to assess the use of HPC, Cord Blood in treating long COVID syndrome and acute stroke.

Leadership Perspective

"With one of the largest inventories of cord blood stem cells worldwide, StemCyte is uniquely positioned to supply, manufacture, and develop advanced cell therapy products," said Dr. Tong Young Lee, CEO of StemCyte. "Looking ahead, we are committed to driving the development of innovative therapies, achieving sustainable growth through diversified business strategies, and solidifying our position as a global leader in the field of cell therapy."

Future Directions

StemCyte International Ltd. is anticipated to be listed on the Taipei Stock Exchange in December 2024, a move that underscores its commitment to advancing regenerative medicine and providing innovative therapies worldwide. StemCyte's public cord blood stem cell inventory adheres to international standards, including those set by the FDA, EMA, TFDA, AABB, and FACT.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Adaptimmune's Lete-cel Receives FDA Breakthrough Therapy Designation for MRCLS

The FDA granted Breakthrough Therapy Designation to Adaptimmune's lete-cel for myxoid/round cell liposarcoma (MRCLS) treatment.
The designation is for patients who have undergone anthracycline-based chemotherapy and meet specific genetic criteria.

StemCyte's HPC Cord Blood Shows Promise in Phase IIa Trial for Post-COVID Fatigue

StemCyte's Phase IIa trial of HPC, Cord Blood (HPC, CB) for Post-COVID syndrome shows significant improvement in fatigue symptoms.
85% of subjects in the cord blood group reported complete relief from fatigue, compared to 20% in the placebo group (p<0.01).

Humacyte's Bioengineered Vessel SYMVESS Receives FDA Approval for Extremity Vascular Trauma

The FDA has approved SYMVESS, Humacyte's acellular tissue-engineered vessel, for treating extremity arterial injuries in adults when urgent revascularization is needed.
SYMVESS offers a readily available alternative to autologous vein grafts, reducing surgical time and avoiding additional incisions in already-injured patients.

RESTEM's ULSC Program Receives FDA Orphan Drug Designation for Polymyositis and Dermatomyositis

RESTEM's umbilical cord outer lining stem cells (ULSCs) program has received FDA Orphan Drug Designation for treating polymyositis (PM) and dermatomyositis (DM).
The ULSC therapy has demonstrated safety, tolerability, and clinically significant improvements in early clinical trials, potentially reducing reliance on steroids.

FDA Approves StemCyte's REGENECYTE, a Cord Blood Stem Cell Therapy

The FDA has approved StemCyte's REGENECYTE, a hematopoietic progenitor cell therapy derived from umbilical cord blood, for certain hematopoietic system disorders.
REGENECYTE is indicated for unrelated donor hematopoietic progenitor cell transplantation in patients with inherited, acquired, or myeloablative treatment-related disorders.

FDA Approves StemCyte's REGENECYTE Cord Blood Therapy for Blood and Immune Disorders

The FDA has approved StemCyte's REGENECYTE, a cord blood stem cell therapy, for treating blood and immune system disorders.
REGENECYTE is an allogeneic hematopoietic stem cell therapy derived from human umbilical cord blood for hematopoietic reconstitution.

FDA Approves StemCyte's REGENECYTE for Blood and Immune System Disorders

The FDA has granted Biologics License Application approval to StemCyte for REGENECYTE, a cord blood stem cell therapy, marking a significant advancement in cell therapy.
REGENECYTE is approved for hematopoietic progenitor cell transplantation in patients with inherited, acquired, or myeloablative treatment-related blood and immune system disorders.

StemCyte's HPC Cord Blood Receives FDA RMAT Designation for Long COVID-19 Treatment

StemCyte's HPC Cord Blood therapy has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA for treating Long COVID-19 syndrome.
The RMAT designation allows StemCyte to expedite the development of HPC Cord Blood, including priority review and accelerated approval opportunities.

FDA Clears IND for Calidi Biotherapeutics' CLD-101 in High-Grade Glioma

The FDA has cleared Northwestern University's IND application for Calidi Biotherapeutics' CLD-101, a stem cell-based oncolytic virus therapy.
A Phase 1b/2 trial will evaluate multiple doses of CLD-101 in patients with newly diagnosed high-grade glioma, commencing in late 2024.

FDA Approves Biotronik's Left Bundle Branch Area Pacing System

The FDA has granted approval for Biotronik's Selectra 3D catheter and Solia S lead system for left bundle branch area pacing (LBBAP).
The approval was based on the BIO-CONDUCT trial, which demonstrated a 95.7% implant success rate and a low 1.7% lead-related complication rate.

Reference News

[1]
U.S. FDA Approves StemCyte Biologics License Application for REGENECYTE™ Cord ...
biospace.com · Nov 22, 2024

StemCyte Inc. announced FDA approval for REGENECYTE™, a cord blood stem cell therapy for blood and immune system disorde...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy